Literature DB >> 2598568

Pharmacokinetics of nicotinic acid-salicylic acid interaction.

R W Ding1, K Kolbe, B Merz, J de Vries, E Weber, L Z Benet.   

Abstract

Both nicotinic acid and salicylic acid undergo glycine conjugation in human beings. Competitive inhibition may therefore be possible when these substances are used concomitantly in patients with hyperlipidemic disorders. The aim of this study was to determine, in six healthy subjects, whether nicotinic acid steady-state levels and total clearance are affected by concomitant aspirin administration. Steady-state nicotinic acid concentrations were obtained in all six volunteers by infusion of nicotinic acid solutions at constant rates (0.075 to 0.100 mg/kg/min) for 6 hours; aspirin (1 gm) was administered orally 120 minutes after the beginning of the infusion of nicotinic acid. Plasma samples were analyzed for nicotinic acid, nicotinuric acid, and salicylic acid. After aspirin administration an immediate marked decrease of nicotinuric acid levels could be observed in all six volunteers, whereas nicotinic acid concentrations increased. We hypothesize that salicylic acid causes a concentration-dependent decrease of total nicotinic acid clearance that results in the saturation (and effective elimination) of the nicotinuric acid conjugation pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598568     DOI: 10.1038/clpt.1989.200

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  The bioavailability of sustained release nicotinic acid formulations.

Authors:  P J Neuvonen; L Roivas; K Laine; O Sundholm
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

2.  Potential vitamin-drug interactions in children: at a pediatric emergency department.

Authors:  Ran D Goldman; Sunita Vohra; Alex L Rogovik
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 3.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 4.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 6.  Antihyperlipidaemic agents. Drug interactions of clinical significance.

Authors:  J A Farmer; A M Gotto
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 7.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 8.  The glycine deportation system and its pharmacological consequences.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Pharmacol Ther       Date:  2012-05-11       Impact factor: 12.310

Review 9.  Mechanisms of flushing due to niacin and abolition of these effects.

Authors:  Aditya Sood; Rohit Arora
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.